N@N

Dr. Daniel L. Farkas, Chairman and CEO of Spectral Molecular Imaging, Presented an Invited Talk at an International Scientific

^{Published on 2010-09-30 01:00:24 - Market Wire}
 

BEVERLY HILLS, Calif.--([ BUSINESS WIRE ])--Cascade Technologies Corp. (OTCBB: [ CSDT ]) announced today that Dr. Daniel L. Farkas, Chairman and CEO of Spectral Molecular Imaging (SMI), CSDT's wholly-owned subsidiary, delivered an invited lecture at a major research conference in Recife, Brazil on September 27^th, 2010.

"it is very important to participate in the worldwide interaction of dedicated researchers who are seeking to develop new and improved ways to image disease for better diagnosis and treatment."

At the Latin America Optics and Photonics Conference, held this week, the Keynote session included talks by Dr. Thomas Baer, immediate past president of OSA; Dr. James Wyant, current OSA President and Dr. Sergio Machado Rezende, Brazila™s Minister of State for Science and Technology.

Dr. Farkas presented in the Photonic-based Therapeutics and Diagnostics oral session immediately following. His talk was entitled New Optical Molecular and Bioimaging Methods for Clinical Applications a" Non-random walks through the translational woods, and focused on innovative ways developed by SMI to enhance resolution, specificity and sensitivity in optical bioimaging as deployed for bench-to-bedside applications yielding clinical uses.

aFor a medical imaging device company such as ours,a said Dr. Farkas, ait is very important to participate in the worldwide interaction of dedicated researchers who are seeking to develop new and improved ways to image disease for better diagnosis and treatment.a aMajor international meetings such as these,a he explained, aare an excellent venue to learn about recent developments, and at the same time communicate our ideas and advances to a community that presents great collaborative opportunities for us. The location of this meeting in South America, with explicit sponsorship and support from the Optical Society of America, presents added chances to directly communicate with colleagues from a very fast-developing geographic area with already outstanding research accomplishments. Needless to say, business opportunities for SMI will also be explored on this trip, especially in Brazil.a

Dr. Farkas has been very active in international meetings through the years, having presented about 200 invited and plenary talks, and having organized and chaired 25 international conferences, mostly in biomedical optics. Within the past year, he lectured at the European Biophysics Congress in Genova, Italy; at the Biomedical Optics Society conference in San Francisco; at the Beckman Laser Institute and Medical Clinic at UC Irvine; at the Electrochemical Society Meeting in Vancouver (two talks); at the Association for Research in Vision and Ophthalmology conference in Ft. Lauderdale; at the International Brain Mapping and Intraoperative Surgical Planning Society congress (New Horizons track) in Bethesda; at the World Congress of Minimally Invasive Spine Surgery in Las Vegas; at the Surgical Navigation division of Medtronic Corporation and in the University of Southern California Physical Sciences in Oncology Center Seminar Series. These talks, and the invitations to present them, reflect the diversity and interdisciplinary nature of the applications enabled by the ground-breaking optical bioimaging that constitutes the core of SMIa™s efforts, and the widespread interest, both scientific and clinical, that they elicit.

About Spectral Molecular Imaging

Spectral Molecular Imaging, Inc., a wholly-owned subsidiary of Cascade Technologies Corp., is a development-stage medical imaging device company, applying its proprietary hyperspectral-optical imaging technologya"originally developed for satellite reconnaissancea"to advance the early and accurate diagnoses of cancer and precancerous conditions. SMI is developing non-invasive, high-resolution optical imaging systems using its patented technology and other proprietary know-how for improved clinical diagnostics, primarily in the field of cancer pathology, by identification and analysis of certain molecular, cellular, and tissue features via hyperspectral-imaging approaches. We expect to provide services related to our primary products, including software modules and maintenance services, and to develop optical diagnostic products that operate in conjunction with surgical and/or evaluation procedures in real time. We believe that our technology will enable early detection and more reliable diagnosis of various diseases, such as melanoma, Barretta™s esophagus (a condition caused by chronic acid reflux that can lead to esophageal cancer) and lung cancer. We expect that medical devices using or based on our developed technology can significantly improve long-term patient outcomes and may substantially reduce overall costs for the healthcare system. For more information, please visit [ http://www.spectralmi.com ].

Forward-Looking Statements

This news announcement contains or may contain certain "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, without limitation, statements regarding SMI's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements are subject to significant risks and uncertainties, including those detailed in filings made by Cascade Technologies Corp., SMI's parent, with the Securities and Exchange Commission. Accordingly we caution our readers that actual results may differ materially from our beliefs or expectations due to economic, business, competitive, market and regulatory factors. We assume no obligation or undertaking to update any forward-looking statements to reflect any changes in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. You should, however, review additional disclosures we make in the reports filed with the Securities and Exchange Commission.